



# How should a positive PCR test result for COVID-19 in an asymptomatic individual be interpreted and managed?

C. Esteve, F.X. Catherine, P. Chavanet, M. Blot, L. Piroth

## ► To cite this version:

C. Esteve, F.X. Catherine, P. Chavanet, M. Blot, L. Piroth. How should a positive PCR test result for COVID-19 in an asymptomatic individual be interpreted and managed?. *Médecine et Maladies Infectieuses* (1971-2020), 2020, 50, pp.633 - 638. <10.1016/j.medmal.2020.09.014>. <hal-03493831>

**HAL Id: hal-03493831**

**<https://hal.science/hal-03493831v1>**

Submitted on 7 Nov 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons CC BY-NC 4.0 - Attribution - Non-commercial use - International License

# How should a positive PCR test result for COVID-19 in an asymptomatic individual be interpreted and managed?

Proposals based on an analysis of the literature available on 1 July 2020

**AUTHORS:** C. Esteve<sup>1</sup>, FX Catherine<sup>1</sup>, P Chavanet<sup>1</sup>, M Blot<sup>1</sup>, L. Piroth<sup>1</sup>

<sup>1</sup>Département d'Infectiologie, CHU de Dijon, 21000 Dijon, France

## Contact

Lionel Piroth  
Département d'Infectiologie - CHU  
14 rue Gaffarel  
21079 Dijon Cedex  
[Lionel.piroth@chu-dijon.fr](mailto:Lionel.piroth@chu-dijon.fr)

**KEY WORDS:** reverse transcriptase PCR; COVID19; coronavirus ; diagnostic

PC, MB and LP were involved in the conception and design of the article.

LP was the coordinator of the article.

CE and FXC were responsible for data collection,

CE and LP wrote the first draft.

All the authors were involved in the interpretation, critically reviewed the first draft, and approved the final version.

## **ABSTRACT:**

The rapidly increasing number of PCR-based SARS-CoV-2 tests as COVID-19 control measures has been leading not only to the discovery of positive results in asymptomatic individuals, but also to the re-testing of persons having contracted (proven or unproven) COVID-19 or having previously tested positive. In the face of interrogations as to the interpretation and management of these types of situations, and given the need to weigh collective and individual risks, we have carried out a review of the literature aimed at responding to the six following questions. Can PCR-based SARS-CoV-2 testing lead to false positives? For how long do the results remain positive? For how long can the results be associated with an actual risk of transmission / with infectivity in a symptomatic person? Is a newly positive PCR-based SARS-CoV-2 test result following one or more negative test results to be associated with a risk of transmission? Is a positive PCR-based SARS CoV-2 test result to be associated with a genuine risk of transmission / with infectivity in an asymptomatic person? Does the presence of antibodies detected by serology attest to control of the infection and consequently to non-contagiousness, even in the event of positive PCR-based SARS-CoV-2 test results? Having been initiated prior to the recently issued recommendations of the *Haut Conseil de la Santé Publique* (French public health council), this review is aimed at synthesizing practical proposals liable to evolve according to the advancement of scientific knowledge and the overall epidemic context.

## 1. Introduction

In December 2019 in Wuhan, China an unexplained outbreak of respiratory distress syndrome occurred. The causal agent was identified as SARS-CoV-2, a new beta coronavirus responsible for COVID19, which brought about not only severe infections in approximately 20% of cases, but also asymptomatic infections in a still insufficiently known proportion of patients. The emerging disease rapidly evolved into a worldwide pandemic, and Europe was chronologically the second most affected continent. Thanks to public health measures involving not only confinement of the French population but also the ever-widening organization of diagnostic testing, by June 2020 COVID incidence had markedly decreased.

Diagnosis during the acute phase of COVID is based on real-time quantitative PCR nasopharyngeal swab testing. Widened access to diagnosis by RT-PCR has entailed validation by the national center of reference of several commercial or in-house kits focusing on multiple targets and exhibiting variable performance. In this context, molecular biology tests facilitate identification of viral RNA, which does not necessarily foreshadow the presence of potentially infectious viruses. Moreover, in some health care establishments PCR-based testing has been extended to systematic screening on admission in view of counteracting viral spread and of monitoring viral excretions prior to the lifting of additional precautionary measures. Given the large number of PCR tests involving more and more asymptomatic patients in a fluctuating epidemic context and given relatively low incidence in present-day France, numerous questions have been put forward on how to interpret molecular biology tests, particularly in asymptomatic persons and with regard to risk of transmission / infectiveness.

We have consequently carried out a review of the literature at our disposal on 10 August 2020 so as to address the different questions underlying interpretation of positive PCR-based SARS Co-V-2 test results in an asymptomatic individual, the objective being to propose an algorithm suited to management of these persons and in accordance with the relevant scientific data. In the absence of official recommendations, the review was initiated before publication on 8 July 2020 of the opinion of the *Haut Conseil de la Santé Publique* (HCSP) (French public health council) (1) pertaining to the course of action to be taken according to SARS-CoV-2 virological status in the framework of screening or contact tracing. The review is aimed at providing supplementary elements, especially as regards the interest of semi-quantitative PCR assay and the limited interest of serology when estimating the risk of contagiousness in this type of evolving situation.

## 2. Can PCR-based SARS-CoV-2 testing lead to false positives?

While the issue of false negatives has been widely taken up in the scientific literature, data on the possibility of false positives are very scarce. That said, a German study has highlighted false positives associated with commercial reagents used for PCR (probes or oligonucleotides), with intensity ranging from low to high (2). Similar incidents have occurred in several European laboratories (3). In comparison with an in-house PCR test of reference, the conclusion following assessment of a commercial Australian PCR test was that false positives were indeed possible (4). Even though their overall likelihood appears low, a multitude of tests during a period of relatively low incidence could lead to a situation in which half of the tests are false positives, particularly in the event of flawed internal and external quality controls (2), as was recently illustrated by an upsurge of false positives in a French department (Meurthe et Moselle) that was associated with contamination of one of the reagents by SARS-CoV-2 RNA (5)

### ***Proposal***

- *While the eventuality of a false positive cannot be totally excluded, no routinely applicable biological modality is presently able to pragmatically sort matters out in the face of positive PCR-based SARS-CoV-2 test results. That is the reason why any and every positive PCR-based SARS-CoV-2 test result must be managed as through it were a true and proven positive.*

### **3. For how long do the results of PCR-based SARS-CoV-2 testing remain positive?**

Out of 155 American patients having undergone a PCR-based control subsequent to an initial positive finding, 88% remained positive 1 to 5 days later, and 56% out of the 105 patients tested afterwards remained positive at 21-25 days (6). Median PCR negativation time in the 56 patients of the Chinese series by Xiao *et al.* was 24 days (7). In Wuhan, 36/378 (9.5%) of patients having tested positive remained positive 30 days later, and in some cases their positivity lasted as long as 83 days (8). The more severe the clinical presentation, the longer the duration of positivity, with a median of 31 days in a Chinese study involving 41 serious cases (9). In a Singaporean study, 32% out of 766 COVID19 patients still remained positive at D21, 22% at D28 and 5% at D33 (10).

Some of the factors reported as being associated with persistently positive tests were delayed hospitalization, a severe form, mechanical ventilation or corticosteroid use, comorbidities such as diabetes and hypertension, male gender and advanced age (7,11). The role of advanced age may have to do with the fact that more often than not, additional utilization of the PCR method constitutes a control preceding transfer to another medicalized structure (6).

#### ***Proposal***

- *It can be estimated that roughly 10 to 30% of persons with positive PCR test results will still have positive PCR results a month later, especially to the extent that their initial viral inoculum level was high, that they were severely diseased and that they were elderly or immunosuppressed.*
- *In the event of persistently positive PCR more than 3 months after initially positive PCR, in the current state of knowledge re-contamination cannot be excluded as a possibility (see question 5).*

#### **4. For how long can the positive results of a PCR-based SARS-CoV-2 test be associated with actual risk of transmission / of infectiousness in a symptomatic individual?**

During the first week of symptoms at the level of the throat there exists an active viral replication of SARS-CoV2, with maximum viral concentrations being reached during the 4<sup>th</sup> or 5<sup>th</sup> day of COVID19 symptoms, and more rapidly in SRAS cases (12).

No viable virus in sputum or at the nasopharyngeal level was found after the 7<sup>th</sup> day of sickness in a German study (12), after the 9<sup>th</sup> day in two American studies (13,14) and after the 11<sup>th</sup> day according to data from Singapore (10).

The above virological data are consistent with epidemiological observations showing that most transmissions occur at a very early stage of the disease (15), with an attack rate among contacts exposed during the first 5 symptomatic days markedly higher than in persons in contact after 5 days (2.4% vs 0% in the event of exposure after the 6<sup>th</sup> day) (16).

Along with models synthesized in two reviews (17,18) and in accordance with recently voiced HCSP opinions (1,19), the above-mentioned virological and epidemiological data allow transmission to be considered as possibly occurring during 10 days following symptom onset.

One potential marker of contagiousness seems to be the cycle threshold value (Ct), which is inversely correlated with quantity of viral RNA; each increase by a factor of 3.3 corresponds to an RNA rate ten times lower (20), and Yu *et al* demonstrated a linear relationship between Ct and RNA rate in upper respiratory tract samples with Ct < 34 (21). In another study, no cultivatable virus was found when the value exceeded 30 (10) or when RNA quantity was lower than 100,000 copies/mL (12). In fact, the cycle threshold value depends on the genomic target of PCR (22,23). When PCR-based SARS-CoV-2 amplifies gene E, the likelihood of finding a viable and cultivatable virus declines, with a 32% reduction of odds ratio by increment of Ct unit, and once Ct exceeds 24, it becomes nil (14). In the Marseille-based study authored by La Scola *et al* (PCR targeting gene E), it was due to the development of subcultures permitting detection in some patients of small quantities of replicating viruses that Ct value reached 34 (24). In another study, according to whether genes nsp12, E and N were amplified, the minimum quantities needed to highlight a viable virus were 5.4, 6 and 5.7 log<sub>10</sub> copies/mL (Ct of 31.47, 31.46 and 35.2, respectively) (25). It is consequently more likely to have a cultivatable virus (and, as a result, a risk of transmissibility) when the PCR(s) target the whole genome, and not just one of the genes (25). Indeed, the notion of genome integrity, which would limit cross-reactions with other coronaviruses, underscores the interest of having several genomic targets, especially in questionable situations (26,27). If it is possible to have on-site access to PCR with two genomic targets (and without a sensitivity deficit identified by the laboratory), only when the two targets are detected will the PCR be confirmed as positive.

To conclude, even though the gold standard allowing for prediction of viral viability varies from one study to the next, it seems important to be cognizant of the Ct (or estimated quantity of RNA) and the number and nature of the targeted gene(s) it is thereby possible to apprise the risk of contamination of an asymptomatic individual with positive PCR and without any notion of previous infection. Given that more often than not, only one gene (gene E) is amplified, cycle threshold value (Ct) exceeding 35 seems associated with contagiousness risk neighboring zero; when Ct is higher than 30, the risk may be considered exceedingly low.

**Proposal**

- *One may estimate, in agreement with the opinion voiced by the HCSP, that infectiveness persists during the first week of symptoms, following which it decreases rapidly, disappearing by the 10<sup>th</sup> day at the latest. There is consequently no risk of contagion 10 days after the symptoms first appear, even in the event of persistently positive PCR SARS-CoV-2 (1,19).*
- *Before 10 days have elapsed, cognizance of the Ct can help to apprise the degree of risk, which is nil when Ct exceeds 35; that much said, its practical interest with regard to a symptomatic person is decidedly low.*



## **5. Is a newly positive PCR-based SARS-CoV-2 test result following one or more negative test results to be associated with a risk of transmission?**

This question concerned as many as 19.8% of the persons having been tested positive for COVID in a study by Brunei (28) and as many as 21.4% in a Wuhan-based study (29). As regards the “Diamond Princess” cruise ship, 35% des passengers who had been hospitalized in a Tokyo hospital center were newly PCR SARS-CoV-2 positive after having tested negative at least one time.

In a Chinese study conducted in Hubei province, the 38 patients with newly positive PCR results were relatively young and had presented with a slightly or moderately severe form of COVID19 (31). None of them presented new signs of COVID and none of their 21 close contacts had been contaminated. In a larger, Korean study, 285 “repositivized” persons were successfully identified (following a mean time interval of 44.9 days), and 44.2% were symptomatic. Among these patients, 108 (with mean real-time PCR Ct values exceeding 30 in 89.5% of cases) underwent viral sample collection, without any viable virus being isolated. Moreover, only 3 out of the 790 identified contact persons presented with positive PCR, which was in all likelihood due to previous exposure, once again without any manifestation of a viable virus, and with neutralizing antibodies being found in 96% of the patients tested. Similar observations were put forward in the Brunei study, where the “repositivized” persons presented with Ct inferior to Ct at the time of diagnosis, and out of 111 tested contact persons, not a single one was contaminated, a finding underlining the non-contagiousness of individuals with “repositivized” PCR (28).

Moreover, clinical and biological data from SARS-CoV-1 (33) and SARS-CoV-2 (34) infections and data from animal models (35) tend to demonstrate the salience of a form of protective immunity subsequent to COVID19, even if it is not presently possible to determine whether it develops in all infected persons and whether remains enduring. A recent French study highlighted the presence of neutralizing antibodies, 28 to 41 days after the appearance of symptoms, in 98% of the caregivers having suffered from moderate forms of the disease (36). Along with the fact that not a single case of new infection has been formally documented in the literature, these findings tend to show that at least in the short and middle term, the potentiality of a new infection remains relatively remote.

However, the above-mentioned humoral immune response seems limited in time, given the diminution of IgG and neutralizing antibodies 2 to 3 months following infection, particularly in paucisymptomatic or asymptomatic forms (37). This was previously reported for other coronaviruses, with reinfection being deemed possible with regard to 3 out of the 4 benign human coronaviruses (38). Repositivized PCR several months after an uneventful time interval consequently raises the possibility of recontamination, all the more so when it is associated with suggestive symptoms (1). In that respect, a three-month time interval has been adopted by the Canadian authorities, who have decided, in relevant cases, to propose supplementary investigations (viral culture, phylogenetic analyses, search for neutralizing antibodies...) (39).

### ***Proposal:***

- *This situation is frequent and should lead to application of the same recommendations as those implemented for symptomatic persons maintaining positive PCR in the middle term, knowing that there is no risk of contagion 10 days after the initial appearance of symptoms.*

- *That said, once 3 months have elapsed since initially positive PCR, in the present-day state of knowledge the possibility of recontamination in the case of newly positive PCR cannot be completely excluded.*

## **6. Is a positive PCR-based SARS-CoV-2 test result to be associated with a genuine risk of transmission / of infectiveness in a person never having previously presented with known COVID?**

Setting aside the improbable issue of potential false positives, an asymptomatic individual can potentially be:

- An unaware pre-symptomatic person,
- An infected person who remains asymptomatic,
- A person who has been asymptomatic with an infection several days or weeks previous, which went unnoticed.

In the hypothetical event of a pre-symptomatic person, the median incubation period approximates 5 days (CI95%, 4.5 to 5.8 days), with 97.5% of the persons developing symptoms within fewer than 10 days (13,40). The contagiousness period begins 2 to 4 days before the symptoms first appear, and is likely to peak 0.7 days before (17,41).

While a Singaporean study did not show transmission from persons remaining asymptomatic (42), it nonetheless remains highly probable that cases of secondary contamination originating in an asymptomatic individual (who has remained asymptomatic) have occurred in the USA (13), in China (43,44) and in Germany (45). Asymptomatic patients could possess a positive PCR SARS-CoV-2 dynamic comparable to that presented by other infected persons (46), with Ct not differing from Ct observed in pre-symptomatic or symptomatic patients (13,47–49), and even in some cases with earlier Ct reduction during asymptomatic infections (50). On the other hand, immunological response appears less pronounced with lower IgG rates, weaker neutralizing antibodies (47), and a lower seroconversion rate (1 patient out of 5) (46) than in symptomatic persons.

There exist no data on correlation between Ct and RNA quantity and likelihood of a viable and cultivatable virus in asymptomatic individuals.

### ***Proposal:***

- *In the absence of data on Ct value (or on estimated viral RNA quantity), any and every asymptomatic person with positive PCR and without preliminary notion of infection must be considered as being potentially at risk, a consideration leading to preventive measures equivalent to those taken with regard to a symptomatic person.*
- *On the other hand, based on present-day knowledge of symptomatic persons, it would probably be of interest to be apprised of the Ct value of the PCR as well as the number of sought-out and positive genes. A value exceeding 35 and/or the positivity of even a single gene could lead to interpretation of the PCR result as probably corresponding to excretion of residual RNA at a time exterior to the period of contagiousness, which would mean that in this case, reinforced preventive measures need not be applied.*
- *While Ct value is known in laboratories, it is not systematically indicated in the reported results. Ideally, however, it should appear in the latter, along with an indication of the targeted gene(s), in addition to the simple indication of positivity.*
- *In some cases, the above considerations should lead to shortening or lightening of reinforced confinement measures, especially when, in addition to the collective elements to be taken into account, the patient's risk/benefit balance legitimates the shortening or lightening.*

## **7. Does the presence of antibodies detected by serology attest to control of the infection and consequently to non-contagiousness, even in the event of positive PCR-based SARS-CoV-2 test results?**

The virus is not suddenly eliminated at the time of seroconversion (12), which at the outset of the 2<sup>nd</sup> week corresponds to a slow but sustained reduction of the viral load contained in sputum (12). Viable viruses have in fact been observed following detection of anti-SARS-CoV2 antibodies (12)(51).

Contrary to what might seem to be suggested in the 8 July 2020 opinion ((19), serology has no impact on either PCR interpretation or short-term management of the persons concerned. And yet, even though a distinction is drawn in the text between asymptomatic positive PSR cases according to whether or not serological test results are positive, in agreement with our proposal this does not lead in clinical practice to any difference in management (see technical sheet #1 of the opinion). As discussed in point 5, it is the existence of proven past COVID-19 infection that conditions the need (or the absence of need) for a patient to be isolated.

### ***Proposal***

- *In the event of positive PCR devoid of any notion of previous or associated symptoms, a serological test will have no impact on either PCR interpretation or short-term management of the persons concerned, regardless of whether the serology is negative, possibly corresponding to a pre-symptomatic phase, or positive, that is to say not excluding the potential presence of a viable virus at the time of the seroconversion.*

## 8. Synthesis of the practical proposals

- While the eventuality of a false positive cannot be totally excluded, no routinely applicable biological modality is presently able to pragmatically sort matters out in the face of a positive PCR-based SARS-CoV-2 test result. That is the reason why any and every positive PCR-based SARS-CoV-2 test result must be managed as though it were a true and proven positive.
- It can be estimated that roughly 10 to 30% of persons with positive PCR test results will still have positive PCR results a month later, especially to the extent that their initial viral inoculum level was high, that they were severely diseased, and/or that they were elderly or immunosuppressed.
- One may estimate that infectiveness persists during the first week of symptoms, following which it decreases rapidly, disappearing by the 10<sup>th</sup> day at the latest, even in the event of persistently positive PCR-based SARS-CoV-2. Before 10 days have elapsed, cognizance of the Ct can help to apprise the degree of risk, which is nil when Ct exceeds 35; that much said, its practical interest with regard to a symptomatic person is decidedly low.
- Detection of positive PCR following a period of transitory negatization is a frequently encountered situation that should lead to application of the same recommendations as those implemented for symptomatic persons maintaining positive PCR in the middle term, knowing that there is no risk of contagion 10 days after the initial appearance of symptoms.
- That said, once 3 months have elapsed since initially positive PCR, in the present-day state of knowledge the possibility of recontamination in the event of newly positive PCR cannot be completely excluded.
- Any and every asymptomatic person with positive PCR and without preliminary notion of infection must be considered as being potentially at risk, a consideration leading to preventive measures equivalent to those taken with regard to a symptomatic person. On the other hand, based on present-day knowledge of symptomatic persons, it would probably be of interest to be apprised of the Ct value of the PCR as well as the number of sought-out and positive genes. A value exceeding 35 and/or the positivity of even a single gene could lead to interpretation of the PCR result as probably corresponding to excretion of residual RNA at a time exterior to the period of contagiousness, which would mean that in this case, reinforced preventive measures need not be applied.
- While the Ct value is known by laboratories, it is not systematically indicated in the reported results. Ideally, however, it should appear in the latter, along with an indication of the targeted gene(s), in addition to the simple indication of positivity.
- On the other hand, in the event of positive PCR devoid of any notion of previous or associated symptoms, a serological test will have no impact on either PCR interpretation or short-term management of the persons concerned, regardless of whether the serology is negative, possibly corresponding to a pre-symptomatic phase, or positive, that is to say not excluding the potential presence of a viable virus at the time of the seroconversion.
- In some cases, the above considerations should lead to shortening or lightening of reinforced confinement measures, especially when, in addition to the collective elements to be taken into account, the patient's risk/benefit balance justifies the shortening or lightening.

The above responses to key questions have led to our proposing an algorithm for management of asymptomatic persons presenting with positive PCR-based SARS-CoV-2 (**Figure 1**). Our proposals will obviously be called upon to evolve in accordance with the advancement of knowledge and the data of the literature. They will also be liable to evolve according to the epidemiological context, and their evolution during a largely inactive epidemic will differ from that to be imagined in the event of renewed and dynamic circulation amidst a possibly insufficiently immunized population.

**DECLARATION OF INTERESTS:** The authors have no conflict of interest to declare.

**ACKNOWLEDGMENTS:** We wish to thank Marielle Buisson, Michel Duong, Sophie Mahy, Arnaud Salmon-Rousseau and Anne Waldner-Combernoux for their constructive suggestions.

## REFERENCES

1. Avis relatif à la conduite à tenir en fonction du statut virologique SARS-CoV-2 chez une personne testée dans le cadre du dépistage ou du contact-tracing. 2020;22.
2. Wernike K, Keller M, Conraths FJ, Mettenleiter TC, Groschup MH, Beer M. Pitfalls in SARS-CoV-2 PCR diagnostics. *Transbound Emerg Dis*. 14 juin 2020;
3. Mögling R, Meijer A, Berginc N, Bruisten S, Charrel R, Coutard B, et al. Delayed Laboratory Response to COVID-19 Caused by Molecular Diagnostic Contamination. *Emerg Infect Dis* [Internet]. août 2020 [cité 13 août 2020];26(8). Disponible sur: [http://wwwnc.cdc.gov/eid/article/26/8/20-1843\\_article.htm](http://wwwnc.cdc.gov/eid/article/26/8/20-1843_article.htm)
4. Rahman H, Carter I, Basile K, Donovan L, Kumar S, Tran T, et al. Interpret with caution: An evaluation of the commercial AusDiagnostics versus in-house developed assays for the detection of SARS-CoV-2 virus. *J Clin Virol Off Publ Pan Am Soc Clin Virol*. 2020;127:104374.
5. Coronavirus : des « dizaines de faux positifs » en Meurthe-et-Moselle à cause d'un réactif de mauvaise qualité [Internet]. France Bleu. 2020 Disponible sur: <https://www.francebleu.fr/infos/sante-sciences/coronavirus-des-dizaines-de-faux-positifs-en-meurthe-et-moselle-a-cause-d-un-reactif-de-mauvaise-1593081349>
6. Ridgway J, Shah N, Robicsek A. Prolonged Shedding of SARS-CoV-2 RNA among Patients with COVID-19. *Infect Control Hosp Epidemiol*. undefined/ed;1-8.
7. Xiao AT, Tong YX, Zhang S. Profile of RT-PCR for SARS-CoV-2: a preliminary study from 56 COVID-19 patients. *Clin Infect Dis*. 19 avr 2020;ciaa460.
8. Li N, Wang X, Lv T. Prolonged SARS-CoV-2 RNA shedding: Not a rare phenomenon. *J Med Virol* [Internet]. [cité 1 juill 2020];n/a(n/a). Disponible sur: <https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25952>
9. Zhou B, She J, Wang Y, Ma X. Duration of Viral Shedding of Discharged Patients With Severe COVID-19. *Clin Infect Dis*. 17 avr 2020;ciaa451.
10. Period Of Infectivity Position Statement [Internet]. Disponible sur: [https://www.ams.edu.sg/view-pdf.aspx?file=media%5c5556\\_fi\\_331.pdf&ofile=Period+of+Infectivity+Position+Statement+\(final\)+23-5-20+\(logos\).pdf](https://www.ams.edu.sg/view-pdf.aspx?file=media%5c5556_fi_331.pdf&ofile=Period+of+Infectivity+Position+Statement+(final)+23-5-20+(logos).pdf)

11. Xu K, Chen Y, Yuan J, Yi P, Ding C, Wu W, et al. Factors Associated With Prolonged Viral RNA Shedding in Patients with Coronavirus Disease 2019 (COVID-19). *Clin Infect Dis*. 9 avr 2020;ciaa351.
12. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-2019. *Nature*. mai 2020;581(7809):465-9.
13. Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. *N Engl J Med*. 28 mai 2020;382(22):2081-90.
14. Bullard J, Dust K, Funk D, Strong JE, Alexander D, Garnett L, et al. Predicting infectious SARS-CoV-2 from diagnostic samples. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 22 mai 2020;
15. Cheng H-Y, Jian S-W, Liu D-P, Ng T-C, Huang W-T, Lin H-H. Contact Tracing Assessment of COVID-19 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods Before and After Symptom Onset. *JAMA Intern Med [Internet]*. 1 mai 2020 [cité 8 juill 2020]; Disponible sur: <https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2765641>
16. Cheng H-Y, Jian S-W, Liu D-P, Ng T-C, Huang W-T, Taiwan COVID-19 outbreak investigation team, et al. High transmissibility of COVID-19 near symptom onset [Internet]. *Infectious Diseases (except HIV/AIDS)*; 2020 mars [cité 1 juill 2020]. Disponible sur: <http://medrxiv.org/lookup/doi/10.1101/2020.03.18.20034561>
17. Byrne AW, McEvoy D, Collins A, Hunt K, Casey M, Barber A, et al. Inferred duration of infectious period of SARS-CoV-2: rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases [Internet]. *Epidemiology*; 2020 avr [cité 14 août 2020]. Disponible sur: <http://medrxiv.org/lookup/doi/10.1101/2020.04.25.20079889>
18. Walsh KA, Jordan K, Clyne B, Rohde D, Drummond L, Byrne P, et al. SARS-CoV-2 detection, viral load and infectivity over the course of an infection. *J Infect*. sept 2020;81(3):357-71.
19. Avis relatif à la conduite à tenir face à un résultat de RT-PCR positif chez une personne ayant des antécédents d'infection par le SARS-CoV-2. 2020;16.
20. Tom MR, Mina MJ. To Interpret the SARS-CoV-2 Test, Consider the Cycle Threshold Value. *Clin Infect Dis*. 21 mai 2020;ciaa619.
21. Yu F, Yan L, Wang N, Yang S, Wang L, Tang Y, et al. Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients. *Clin Infect Dis*. 28 juill 2020;71(15):793-8.
22. Binnicker MJ. Can the SARS-CoV-2 PCR Cycle Threshold Value and Time from Symptom Onset to Testing Predict Infectivity? *Clin Infect Dis Off Publ Infect Dis Soc Am*. 6 juin 2020;
23. Nalla AK, Casto AM, Huang M-LW, Perchetti GA, Sampoleo R, Shrestha L, et al. Comparative Performance of SARS-CoV-2 Detection Assays Using Seven Different Primer-Probe Sets and One Assay Kit. *J Clin Microbiol*. 26 2020;58(6).
24. La Scola B, Le Bideau M, Andreani J, Hoang VT, Grimaldier C, Colson P, et al. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. *Eur J Clin Microbiol Infect Dis*. 27 avr 2020;1-3.

25. Huang C-G, Lee K-M, Hsiao M-J, Yang S-L, Huang P-N, Gong Y-N, et al. Culture-based virus isolation to evaluate potential infectivity of clinical specimens tested for COVID-19. *J Clin Microbiol*. 9 juin 2020;
26. Farfour E, Jolly E, Pascreau T, Asso-Bonnet M, Mazaux L, Vasse M, et al. SARS-CoV-2 RT-PCR: at least 2 viral targets are needed. *Infect Dis*. 2 août 2020;52(8):583-4.
27. Caruana G, Croxatto A, Coste AT, Opota O, Lamoth F, Jaton K, et al. Diagnostic strategies for SARS-CoV-2 infection and interpretation of microbiological results. *Clin Microbiol Infect*. sept 2020;26(9):1178-82.
28. Wong J, Koh WC, Momin RN, Alikhan MF, Fadillah N, Naing L. Probable causes and risk factors for positive SARS-CoV-2 test in recovered patients: Evidence from Brunei Darussalam. *J Med Virol*. 19 juin 2020;
29. Xiao AT, Tong YX, Zhang S. False-negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: Rather than recurrence. *J Med Virol* [Internet]. [cité 1 juill 2020];n/a(n/a). Disponible sur: <https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25855>
30. Miyamae Y, Hayashi T, Yonezawa H, Fujihara J, Matsumoto Y, Ito T, et al. Duration of viral shedding in asymptomatic or mild cases of novel coronavirus disease 2019 (COVID-19) from a cruise ship: A single-hospital experience in Tokyo, Japan. *Int J Infect Dis IJID Off Publ Int Soc Infect Dis*. 11 juin 2020;
31. An J, Liao X, Xiao T, Tian S, Yuan J, Ye H, et al. Clinical characteristics of the recovered COVID-19 patients with re-detectable positive RNA test. 2020.
32. 문서뷰어[Internet]. [cité 1 juill 2020]. Disponible sur: [https://is.cdc.go.kr/upload\\_comm/syview/doc.html?fn=159118745823700.pdf&rs=/upload\\_comm/docu/0030/](https://is.cdc.go.kr/upload_comm/syview/doc.html?fn=159118745823700.pdf&rs=/upload_comm/docu/0030/)
33. Hofmann H, Pyrc K, van der Hoek L, Geier M, Berkhout B, Pöhlmann S. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. *Proc Natl Acad Sci U S A*. 31 mai 2005;102(22):7988-93.
34. To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C, Lung DC, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *Lancet Infect Dis*. mai 2020;20(5):565-74.
35. Bao L, Deng W, Gao H, Xiao C, Liu J, Xue J, et al. Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2 [Internet]. *Microbiology*; 2020 mars [cité 2 juill 2020]. Disponible sur: <http://biorxiv.org/lookup/doi/10.1101/2020.03.13.990226>
36. Fafi-Kremer S, Bruel T, Madec Y, Grant R, Tondeur L, Grzelak L, et al. Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France. *medRxiv*. 22 mai 2020;2020.05.19.20101832.
37. Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. *JAMA*. 9 juin 2020;323(22):2249.
38. Kirkcaldy RD, King BA, Brooks JT. COVID-19 and Postinfection Immunity: Limited Evidence, Many Remaining Questions. *JAMA*. 9 juin 2020;323(22):2245.



39. Prise en charge des personnes considérées rétablies et présentant à nouveau un test positif pour le SRAS-CoV-2. :11.
40. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. *Ann Intern Med*. 10 mars 2020;172(9):577-82.
41. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat Med*. mai 2020;26(5):672-5.
42. Wei WE. Presymptomatic Transmission of SARS-CoV-2 — Singapore, January 23–March 16, 2020. *MMWR Morb Mortal Wkly Rep* [Internet]. 2020 [cité 1 juill 2020];69. Disponible sur: <https://www.cdc.gov/mmwr/volumes/69/wr/mm6914e1.htm>
43. Bai Y, Yao L, Wei T, Tian F, Jin D-Y, Chen L, et al. Presumed Asymptomatic Carrier Transmission of COVID-19. *JAMA*. 14 avr 2020;323(14):1406-7.
44. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* [Internet]. 28 févr 2020 [cité 9 juill 2020]; Disponible sur: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092819/>
45. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. *N Engl J Med*. 5 mars 2020;382(10):970-1.
46. Yongchen Z, Shen H, Wang X, Shi X, Li Y, Yan J, et al. Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients. *Emerg Microbes Infect*. 1 janv 2020;9(1):833-6.
47. Long Q-X, Tang X-J, Shi Q-L, Li Q, Deng H-J, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. *Nat Med*. 18 juin 2020;1-5.
48. Kimball A. Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility — King County, Washington, March 2020. *MMWR Morb Mortal Wkly Rep* [Internet]. 2020 [cité 17 août 2020];69. Disponible sur: <https://www.cdc.gov/mmwr/volumes/69/wr/mm6913e1.htm>
49. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. *N Engl J Med*. 19 mars 2020;382(12):1177-9.
50. Uhm J-S, Ahn JY, Hyun JH, Sohn Y, Kim JH, Jeong SJ, et al. Patterns of Viral Clearance in the Natural Course of Asymptomatic Coronavirus Disease 2019 (COVID-19): Comparison with Symptomatic Nonsevere COVID-19. *Int J Infect Dis*. août 2020;S1201971220306202.
51. Liu W-D, Chang S-Y, Wang J-T, Tsai M-J, Hung C-C, Hsu C-L, et al. Prolonged virus shedding even after seroconversion in a patient with COVID-19. *J Infect*. avr 2020;S0163445320301900.

**Figure 1: Proposed algorithm for management of an asymptomatic person with positive PCR SARS-CoV-2 (as of 10 August 2020)**

